KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
<p>Abstract</p> <p>Background</p> <p>We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-κB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-07-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | http://www.translational-medicine.com/content/7/1/63 |